Sermorelin has a history none of the other compounds in this family can claim. It was an approved prescription drug in the United States from 1997, it was used in hospitals as a diagnostic test, and it came off the market in 2008 for commercial reasons rather than because anything went wrong with it. That history is why the safety picture here is unusually well filled in, and why there's a legal route to this compound that most of the peptide market doesn't have. Below is what people actually run, and what that history does and doesn't buy you.
Vial size isn't part of what follows, since the amount of bacteriostatic water you add sets your concentration either way. Our reconstitution calculator handles that math for whatever vial and target amount you're working with.
What it is
Sermorelin is the working front end of growth hormone-releasing hormone. The natural signal is 44 amino acids long; sermorelin is the first 29 of them, and those 29 turned out to carry the entire ability to bind the pituitary receptor and trigger a release. The rest of the molecule does nothing you need. It's the shortest version of that signal that still works, which is what it was characterised as decades ago.
It's also the least modified compound in this family. Tesamorelin has a stabilising group added, CJC-1295 has either a stabilising change or an albumin anchor depending on which version you have, and sermorelin has neither. That means it behaves closest to the natural signal, and it clears fast, in minutes rather than hours or days.
The regulatory history matters here more than usual. Sermorelin was approved in 1997 as Geref, for diagnosing and treating growth hormone deficiency in children. It was withdrawn from the US market in 2008, and the withdrawal was voluntary and commercial rather than a safety action. No approved product exists now. But because it was once a regulated drug with an established profile, licensed compounding pharmacies still prepare it on prescription, which puts a legal, pharmacy-grade route on the table that simply doesn't exist for CJC-1295 or ipamorelin.
What people use it for
The general growth hormone case again: sleep, recovery, body composition, and the sense that repair slowed down. Sermorelin's particular pull in this audience is that it's the gentlest-sounding option in the family, and there's something behind that impression rather than nothing. It's the least altered version of a signal the body already sends, it clears quickly, and it leans hardest on the pituitary deciding how much to release rather than being pushed.
The second reason people land here is the prescription route. For anyone uncomfortable buying research-grade material from a website, a compounding pharmacy working from a prescription is a genuinely different proposition, with a pharmacist and a prescriber in the loop and a product made to pharmacy standards. It costs more. Whether that trade is worth it is a real question rather than an obvious one, and it's yours to weigh.
Formulations
Sermorelin ships as a lyophilized powder for subcutaneous injection. Across the research vendors we track, 10 mg vials are the most common with 5 mg close behind, and 2 mg is now rare. Compounded pharmacy preparations come in their own sizes and often already reconstituted, which changes the storage arithmetic below completely, so read the pharmacy's own instructions rather than this page's if that's your route.
Because it clears in minutes, there's no long-acting version of sermorelin and no weekly schedule. Anything sold as a long-acting version of this signal is a different molecule with a different name.
Dosing protocols
Two separate conventions circulate for this compound, and unusually, one of them traces to a real approved product's own labelling rather than to the market talking to itself.
See the Sermorelin research notes for the research behind these figures.
| Pattern | Amount | How often | Where it comes from |
|---|---|---|---|
| Most commonly referenced | 200–300 mcg | Nightly, before sleep, empty stomach | Repeated across vendor education pages, with no named clinician behind it. |
| Compounding-pharmacy range | 200–500 mcg | Nightly | The wider band described where sermorelin is prescribed and compounded. A prescriber sets the figure, which is the one place in this whole category where somebody qualified is choosing the number. |
| What the approved product used | 30 mcg per kg of body weight | Once daily at bedtime | The labelling of the approved children's product, dosed by body weight, for growth hormone deficiency in children rather than for anything an adult reading this wants. Included because it is the only figure here set by a regulator, and because it lands well above what circulates. |
All patterns above are subcutaneous injection.
What that last row is doing there
That approved figure is dosed by body weight, and it's worth converting once so it isn't just an abstraction. Thirty micrograms per kilogram, for someone of about 165 pounds, works out near 2,250 mcg a day, which is seven to eleven times the amount that circulates for adults. Read that gap carefully, because it cuts both ways and vendor copy tends to use only the half that suits it.
It does mean the community amounts sit far below a figure a regulator was once willing to approve, which is a reassuring thing to know about tolerability. It does not mean more is better here. That amount was set for children with a diagnosed deficiency, growing, being monitored, for an outcome nobody reading this is pursuing. A number from a different population and a different purpose isn't a target, it's context.
Amount total, for planning your vial purchase. At 300 mcg nightly, a twelve-week stretch runs 25.2 mg (300 mcg times 84 nights), so between two and three 10 mg vials. Compare vendors against that figure, and against a compounding pharmacy quote if the prescription route is open to you.
How much to reconstitute at once. A reconstituted vial keeps about 28 days refrigerated, and at 300 mcg nightly that window uses 8.4 mg. So a 10 mg vial slightly overshoots it, leaving about 1.6 mg to expire, and a 5 mg vial runs out in 16 or 17 nights. At the lighter 200 mcg amount the window only reaches 5.6 mg, and a 10 mg vial wastes nearly half. Working example: 5 mg into 2 mL of bacteriostatic water gives 2,500 mcg per mL, so 300 mcg is 300 divided by 2,500, times 100, which is 12 units on a standard U-100 insulin syringe, and 200 mcg is 8 units. See how much to reconstitute at once for the general math.
Cycling guidelines
Three to six months continuously, then a break, is the pattern most often described where sermorelin is prescribed, and it's noticeably longer than the twelve-weeks-on-four-off convention that circulates for the research-grade compounds. Both appear in practice.
The argument for running it longer rests on the same property that makes it feel gentle: because it clears in minutes and leans on the pituitary's own decision about how much to release, there's less concern about holding a signal on continuously than there is with a long-acting compound. That's reasoning rather than a tested schedule, but it's reasoning grounded in something real about the molecule.
Signs a course is commonly stopped or reconsidered:
- Water retention or puffiness in the hands and face
- Numbness or tingling in the hands
- Persistent redness, swelling or itching at injection sites, which is the most commonly reported complaint on this compound specifically
- Headaches or flushing that don't settle over the first couple of weeks
- Blood sugar drifting upward
Stacking
Most commonly paired stack: Sermorelin with Ipamorelin.
Rationale: the same two-doors argument that drives the whole category. Sermorelin works on the growth hormone-releasing hormone receptor; Ipamorelin works on the ghrelin receptor. Both clear quickly, which makes them a natural timing match, and this pairing is a direct alternative to the more commonly sold CJC-1295 no-DAC and Ipamorelin blend.
Protocol as run: both before sleep on an empty stomach, as two injections, commonly 200 to 300 mcg of each. Sermorelin is rarely sold premixed with anything, so this stack is usually two vials by default, which incidentally gives you the ratio control the premixed blends take away.
Where it appears in the older literature: sermorelin also shows up alongside GHRP-2 and GHRP-6 in the research on multi-compound growth hormone protocols, which is worth knowing when you meet those combinations described as established. Those are the older, less selective compounds ipamorelin was designed to improve on.
Lighter stacks: BPC-157 as a general recovery pairing, on a rationale unrelated to growth hormone.
Combinations to approach carefully: CJC-1295 and tesamorelin both work through the same receptor sermorelin does. Running sermorelin alongside either isn't combining two signals, it's doubling one, and paying twice for it.
Expected results timeline
First week or two: sleep, described as deeper and as waking less, which is the most consistent early report across this category.
Months in: recovery and, more slowly, body composition. The longer three-to-six-month convention exists partly because this is where the changes people are after are described as showing up.
Extended, continued use: the pediatric research ran up to three years, which is far longer than anything else in this family has been studied for, and the compound held up over that stretch. What that tells you about a healthy adult in midlife is limited, but it isn't nothing.
What to expect realistically: sermorelin's evidence is unusually deep in the wrong places for this audience. It was well studied as a diagnostic test and in children with a diagnosed deficiency, where it reliably raised growth hormone and increased growth, though generally less than injected growth hormone did. In adults with age-related decline, which is what most people reading this are after, the evidence is mostly reviews, retrospective looks and case series rather than controlled work. So the compound is well characterised and the specific use is not, and those are different things.
Administration technique
- The lyophilized powder is reconstituted with bacteriostatic water, at a concentration set by the reconstitution calculator for the target amount. Compounded preparations may arrive already in solution, in which case the pharmacy's instructions replace this step.
- The solution is swirled gently to dissolve rather than shaken, since agitation can degrade the peptide.
- The calculated volume is drawn into an insulin syringe, which at 8 to 12 units is the only thing that measures this accurately.
- A subcutaneous site is chosen, commonly the abdomen, with sites rotated night to night. Rotation matters more on this compound than most, since injection site reactions are its most commonly reported complaint.
- The skin is pinched and the injection given at roughly a 45-degree angle.
- The dose is given at bedtime, at least two hours after eating, since food raises insulin and insulin blunts the release this is meant to produce. The bedtime timing here matches the approved product's own labelling rather than being convention alone.
Side effects and safety
Common: injection site reactions lead, and they're reported more often for sermorelin than for the rest of this family: redness, swelling or itching at the site, usually mild and settling on its own. Flushing and headaches follow.
Less common: water retention and puffiness, dizziness, a metallic taste in the mouth shortly after the injection, and numbness or tingling in the hands. A rise in blood sugar is the one worth watching most closely, as with everything in this category.
What we know, unusually: this is the one compound in this family where the safety picture is genuinely filled in, because it carried an approved product for eleven years and was given to children under monitoring for up to three years at a time. That's a real body of tolerability data and it's the strongest single argument for sermorelin over its neighbours.
What we don't know: what it does for the reasons adults actually run it. The deep evidence is in children with a diagnosed deficiency and in diagnostic testing. Long-run use in healthy adults for sleep, recovery or body composition hasn't been studied in controlled work, and research-grade material bought online isn't made to the standard the approved product was.
Contraindications: active cancer is the caution carried across this category, on the reasoning that raising growth hormone and IGF-1 signalling could in principle accelerate cell growth. Pregnancy, breastfeeding and use in minors outside medical supervision have no basis here. Untreated hypothyroidism blunts the growth hormone response and was flagged on the approved product's own labelling, which makes it a more concrete caution than most on this page.
Drug interactions: thyroid hormone status affects the response directly. Corticosteroids interact with growth hormone signalling, and anything affecting blood sugar control is worth knowing about.
Sermorelin vs. CJC-1295
These two are the closest comparison on the site: the same signal, one left almost as the body makes it and one engineered to last. The choice between them is mostly a choice about how long you want the signal on, and how much regulatory history you want behind it.
| Sermorelin | CJC-1295 | |
|---|---|---|
| How long it lasts | Minutes. A brief pulse, closest to the natural signal | Six to eight days with DAC; about half an hour without it |
| Frequency | Nightly | Weekly with DAC; nightly or more without it |
| Regulatory history | Approved 1997, withdrawn 2008 for commercial reasons. Still compounded on prescription | Never approved anywhere, no prescription route |
| Safety picture | Well filled in, from years of approved use including in children | Thin. Small numbers of healthy adults, over weeks |
| Main catch | The deep evidence is for a use nobody here is pursuing | Two different compounds share the name |
Choose sermorelin if: the safety history matters to you, or the compounding-pharmacy route is one you'd rather take, and nightly injection is acceptable.
Choose CJC-1295 if: weekly dosing is the deciding factor, or you're building the standard pairing with ipamorelin where the short no-DAC version is the conventional partner.
See the full CJC-1295 and sermorelin comparison for the head-to-head, the CJC-1295 guide and protocols for its own dosing, and the ipamorelin guide for the compound both are commonly paired with.
Storage and handling
Lyophilized powder: refrigerate at 2 to 8°C and protect from light. Kept frozen, the unreconstituted powder is commonly described as stable considerably longer, which is the practical answer to a 10 mg vial that overshoots its own 28-day window. Take lot-specific stability from the vendor's certificate of analysis.
Reconstituted solution: refrigerate and use within about 28 days. A compounded pharmacy preparation comes with its own dated expiry, which is set for that specific preparation and replaces the general figure rather than sitting alongside it.
Signs of degradation:
- Cloudiness or visible particles in a solution that was previously clear
- Discoloration of the powder or the reconstituted liquid
- Powder that has clumped or gone sticky, which usually means moisture reached it
FAQ
Was this really an approved drug? Yes, from 1997 to 2008 in the United States, for diagnosing and treating growth hormone deficiency in children. It was withdrawn voluntarily for commercial reasons, not because of a safety finding.
Can I get it by prescription? Licensed compounding pharmacies still prepare it on a prescription, which is a legal, pharmacy-grade route that doesn't exist for most compounds on this site. It costs more than research-grade material.
How much do people run? 200 to 300 mcg nightly is the circulating figure; prescribed and compounded ranges run somewhat wider, up to about 500 mcg.
Why is the approved children's amount so much higher? It was dosed by body weight, for a diagnosed deficiency, in growing children under monitoring. It tells you something useful about tolerability and nothing about what an adult should run.
Sermorelin or CJC-1295? Sermorelin for the safety history and the prescription route. CJC-1295 for weekly dosing, or if you're building the standard ipamorelin pairing.
Why the injection site reactions? They're this compound's most commonly reported complaint, usually mild. Rotating sites is the standard answer.
How long do people run it? Three to six months continuously where it's prescribed, or the shorter twelve-on-four-off convention that circulates for research-grade compounds. Both are in use.
How is it stored? Refrigerated and out of the light, frozen if unreconstituted and being kept a while, used within about 28 days once mixed. A compounded preparation follows its own dated expiry.
Bottom line
Key dosing takeaways:
- 200 to 300 mcg nightly at bedtime on an empty stomach is what circulates, with prescribed ranges running somewhat wider
- The approved children's product was dosed by body weight and lands far above the adult convention, which is context on tolerability rather than a target
- It clears in minutes, so there's no weekly version of this compound and nothing sold as one is sermorelin
Best practices:
- Pricing it against a compounding pharmacy quote as well as against research vendors, since this is one of the few compounds here where that route exists
- Rotating injection sites deliberately, since site reactions are this compound's signature complaint
- Reconstituting to match the 28-day window rather than the vial, since a 10 mg vial slightly overshoots it at 300 mcg nightly
Works best for people who:
- Want the compound in this family with a real safety history behind it
- Would rather go through a prescriber and a pharmacy than a website, and will pay for that
- Can hold that the deep evidence is for a different population and a different purpose than their own
Research-grade sermorelin is sold for research, and the well-studied use behind it is not the one most people reading this are pursuing. You already know that. You're an adult making an informed call about your own body, and that's yours to make.
Sources
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging. 2006;1(4):307–308. The argument that stimulating the pituitary's own release preserves feedback that injected growth hormone bypasses. PubMed ↗
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139–157. Source for the diagnostic use, the pediatric height-velocity results over periods up to 36 months, and the comparison against injected growth hormone. PubMed ↗
- Frohman LA, Jansson JO. Growth hormone releasing hormone. Endocrine Reviews. 1986;7(3):223–253. The foundational work establishing that the first 29 amino acids carry the full receptor-binding activity of the natural signal. PubMed ↗
- Sinha DK, Balasubramanian A, Tatem AJ, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology. 2020;9(Suppl 2):S149–S159. Source for the observation that the adult body-composition evidence in this class remains largely observational. PubMed ↗